# Stanford V
> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Stanford_V
> Markdown URL: https://mediated.wiki/source/Stanford_V.md
> Source: https://en.wikipedia.org/wiki/Stanford_V
> Source revision: 1296154262
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)
'''Stanford V''' (usually spoken as ''Stanford Five''), is a [chemotherapy regimen](/source/chemotherapy_regimen) (with accompanying [radiation therapy](/source/radiation_therapy)) intended as a [first-line treatment](/source/first-line_treatment) for [Hodgkin lymphoma](/source/Hodgkin_lymphoma). The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as [ABVD](/source/ABVD).[{{cite journal |vauthors=Bartlett NL, Rosenberg SA, Hoppe RT, etal |title=Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report |journal=J. Clin. Oncol. |volume=13 |issue=5 |pages=1080–1088 |year=1995 |doi=10.1200/JCO.1995.13.5.1080 |pmid=7537796 }}] The chemical agents used are:
* A [mustard derivative](/source/Nitrogen_mustard) such as [cyclophosphamide](/source/cyclophosphamide), [chlormethine](/source/chlormethine) or [ifosfamide](/source/ifosfamide)
* [Doxorubicin](/source/Doxorubicin), an anti-tumor [antibiotic](/source/antibiotic)
* [Vinblastine](/source/Vinblastine), an [alkaloid](/source/alkaloid) cell toxin
* [Vincristine](/source/Vincristine), another alkaloid cell toxin
* [Bleomycin](/source/Bleomycin), another anti-tumor antibiotic
* [Etoposide](/source/Etoposide), a [DNA](/source/DNA) toxin
* [Prednisone](/source/Prednisone), a [corticosteroid](/source/corticosteroid)
==Drug Regimen==
The chemotherapy part of Stanford V treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. In many cases, this is followed by [radiation therapy](/source/radiation_therapy) for anywhere from 2 to 6 weeks to the affected areas of the body.
Stanford V is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other Hodgkin lymphoma treatments. However, in a randomized controlled study, Stanford V was inferior to ABVD.[{{cite journal |title=ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi |journal=J. Clin. Oncol. |volume=23 |issue=36 |pages=9198–207 |year=2005 |pmid=16172458 |doi=10.1200/JCO.2005.02.907
|first1= PG |last1=Gobbi
|first2=A |last2=Levis
|first3=T |last3=Chisesi
|first4=C |last4= Broglia
| display-authors = 3
|doi-access=free |hdl=11380/3063 |hdl-access=free }}] This study has been criticize for not adhering to the proper Stanford V protocol. Specifically, the radiation therapy component following chemotherapy was not properly administered in the Italian study. A retrospective study from the Memorial Sloan-Kettering Cancer Center displayed results similar to the Stanford Cancer Center's own experience. The study concluded that, "Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL."[{{cite journal |vauthors=Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J |title=Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. |journal=Ann. Oncol. |volume=21 |issue=3 |pages=574–81 |year=2010 |pmid=19759185 |doi=10.1093/annonc/mdp337|doi-access=free }}]
{| class="wikitable"
|-
! Drug[{{cite web|title=Cancer Care Ontario|url=http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=12424|work=Formulary|accessdate=2011-05-27}}][{{cite journal|last=Horning|first=SJ|author2=Williams J, Bartlett NL|title=Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492|journal=Journal of Clinical Oncology| date=March 2000 |volume=18|issue=5|pages=972–980|display-authors=etal|pmid=10694546|doi=10.1200/jco.2000.18.5.972}}] !! Dose !! Mode !! Days
|-
| [Doxorubicin](/source/Doxorubicin) || 25 mg/m2 || IV || Days 1 and 15
|-
| [Vinblastine](/source/Vinblastine) || 6 mg/m2 || IV || Days 1 and 15
|-
| [Chlormethine](/source/Chlormethine) || 6 mg/m2 || IV || Day 1
|-
| [Vincristine](/source/Vincristine) || 1.4 mg/m2 (max 2 mg) || IV || Days 8 and 22
|-
| [Bleomycin](/source/Bleomycin) || 5 units/m2 || IV || Days 8 and 22
|-
| [Etoposide](/source/Etoposide) || 60 mg/m2 || IV || Days 15, 16
|-
| [Prednisone](/source/Prednisone) || 40 mg/m2 || PO || Q2D
|}
==References==
==External links==
* [http://www.lymphomainfo.net/therapy/chemotherapy/stanfordv.html Lymphoma Information Network]
* {{cite journal | pmid = 11821442 | volume=20 | issue=3 | title=Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial | date=February 2002 |vauthors=Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA | journal=J. Clin. Oncol. | pages=630–7 | doi=10.1200/jco.20.3.630}}
* [http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=12424 Includes table for schedule]
{{Chemotherapeutic Agents}}
Category:Chemotherapy regimens used in lymphoma
Category:Hodgkin lymphoma
---
Adapted from the Wikipedia article [Stanford V](https://en.wikipedia.org/wiki/Stanford_V) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Stanford_V?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.